|
humans |
214 |
|
covid-19 |
174 |
|
female |
133 |
|
male |
133 |
|
animals |
126 |
|
adult |
124 |
|
sars-cov-2 |
122 |
|
middle aged |
103 |
|
coronavirus |
87 |
|
influenza |
80 |
|
hong kong - epidemiology |
79 |
|
aged |
76 |
|
phylogeny |
71 |
|
molecular sequence data |
68 |
|
hong kong |
63 |
|
child |
62 |
|
mice |
61 |
|
adolescent |
59 |
|
child, preschool |
59 |
|
base sequence |
54 |
|
infant |
54 |
|
polymerase chain reaction |
54 |
|
children |
52 |
|
disease outbreaks |
52 |
|
epidemiology |
51 |
|
sequence analysis, dna |
50 |
|
genotype |
49 |
|
amino acid sequence |
48 |
|
cell line |
46 |
|
reverse transcriptase polymerase chain reaction |
46 |
|
viral load |
46 |
|
antiviral |
45 |
|
h5n1 |
45 |
|
molecular epidemiology |
45 |
|
time factors |
44 |
|
china - epidemiology |
43 |
|
sars-cov |
43 |
|
transmission |
42 |
|
influenza virus |
41 |
|
risk factors |
41 |
|
china |
40 |
|
influenza a virus |
40 |
|
medical sciences |
40 |
|
treatment outcome |
40 |
|
vaccine |
40 |
|
cohort studies |
39 |
|
pathogenesis |
39 |
|
incidence |
38 |
|
interferon |
38 |
|
cell line, tumor |
37 |
|
prospective studies |
37 |
|
retrospective studies |
37 |
|
diagnosis |
36 |
|
infection |
36 |
|
sars |
36 |
|
sensitivity and specificity |
36 |
|
severe acute respiratory syndrome |
36 |
|
virulence |
36 |
|
virus replication |
36 |
|
antibodies, viral - blood |
35 |
|
pandemic |
35 |
|
rna, viral - genetics |
35 |
|
aged, 80 and over |
34 |
|
cattle |
34 |
|
mutation |
34 |
|
genome, viral |
33 |
|
microbial sensitivity tests |
33 |
|
prevalence |
33 |
|
bronchiectasis |
32 |
|
nasopharyngeal carcinoma |
32 |
|
sars coronavirus |
32 |
|
cells, cultured |
31 |
|
sequence homology, amino acid |
31 |
|
treatment |
31 |
|
anti-bacterial agents - pharmacology |
29 |
|
case-control studies |
29 |
|
pandemics |
29 |
|
seasons |
29 |
|
severity of illness index |
29 |
|
vaccination |
29 |
|
evolution, molecular |
28 |
|
flavivirus |
28 |
|
follow-up studies |
28 |
|
genetic variation |
28 |
|
phenotype |
28 |
|
young adult |
28 |
|
chemicals and cas registry numbers |
27 |
|
enzyme-linked immunosorbent assay |
27 |
|
human |
27 |
|
immune response |
27 |
|
apoptosis |
26 |
|
blotting, western |
26 |
|
enterovirus |
26 |
|
hemagglutinin |
26 |
|
immunocompromised host |
26 |
|
mers-cov |
26 |
|
sequence alignment |
26 |
|
ace2 |
25 |
|
birds - virology |
25 |
|
burkholderia pseudomallei |
25 |
|
evolution |
25 |
|
fatal outcome |
25 |
|
hospitalization |
25 |
|
inhibitor |
25 |
|
lipidomics |
25 |
|
metabolomics |
25 |
|
mice, inbred balb c |
25 |
|
models, molecular |
25 |
|
neutralization tests |
25 |
|
risk assessment |
25 |
|
serotyping |
25 |
|
amino acid substitution |
24 |
|
antiviral agents - therapeutic use |
24 |
|
chiroptera - virology |
24 |
|
gene expression |
24 |
|
genetic predisposition to disease |
24 |
|
h7n9 |
24 |
|
influenza, human - epidemiology - virology |
24 |
|
serology |
24 |
|
zika |
24 |
|
antigens, viral - analysis |
23 |
|
epstein-barr virus |
23 |
|
flow cytometry |
23 |
|
genome |
23 |
|
influenza a virus, h1n1 subtype - immunology |
23 |
|
molecular sequence numbers |
23 |
|
survival rate |
23 |
|
swine - virology |
23 |
|
up-regulation |
23 |
|
age factors |
22 |
|
bone marrow transplantation |
22 |
|
bone marrow transplantation - adverse effects |
22 |
|
chinese |
22 |
|
dogs |
22 |
|
feces - virology |
22 |
|
hemagglutination inhibition tests |
22 |
|
mouse |
22 |
|
neutralizing antibody |
22 |
|
omicron |
22 |
|
polymerase chain reaction - methods |
22 |
|
swine |
22 |
|
temperature |
22 |
|
viral replication |
22 |
|
antibody |
21 |
|
bat |
21 |
|
cercopithecus aethiops |
21 |
|
cluster analysis |
21 |
|
cytokine |
21 |
|
mucosal immunity |
21 |
|
prognosis |
21 |
|
transcription, genetic |
21 |
|
animal |
20 |
|
asthma |
20 |
|
avian influenza |
20 |
|
bacterial typing techniques |
20 |
|
biomarkers |
20 |
|
birds |
20 |
|
cloning, molecular |
20 |
|
cytokines |
20 |
|
melioidosis |
20 |
|
novel |
20 |
|
outbreak |
20 |
|
polymorphism, genetic |
20 |
|
protein structure, tertiary |
20 |
|
saliva |
20 |
|
sars virus - immunology |
20 |
|
species specificity |
20 |
|
tuberculosis |
20 |
|
viral proteins - genetics |
20 |
|
antimicrobial resistance |
19 |
|
biomarker |
19 |
|
cricetinae |
19 |
|
cross protection |
19 |
|
disease outbreaks - statistics & numerical data |
19 |
|
disease reservoirs - virology |
19 |
|
dna primers |
19 |
|
dna, viral - genetics |
19 |
|
gene silencing |
19 |
|
genes, viral |
19 |
|
immunity |
19 |
|
influenza, human - virology |
19 |
|
mrsa |
19 |
|
nasopharynx - virology |
19 |
|
promoter regions, genetic |
19 |
|
reproducibility of results |
19 |
|
respiratory system - virology |
19 |
|
signal transduction |
19 |
|
spike protein |
19 |
|
susceptibility |
19 |
|
virus replication - drug effects |
19 |
|
administration, oral |
18 |
|
adolescents |
18 |
|
animal experiment |
18 |
|
gene expression regulation |
18 |
|
hamster |
18 |
|
hela cells |
18 |
|
influenza a virus, h1n1 subtype - genetics |
18 |
|
influenza a virus, h1n1 subtype - genetics - pathogenicity |
18 |
|
influenza in birds - virology |
18 |
|
influenza vaccine |
18 |
|
lung - radiography |
18 |
|
microscopy, electron |
18 |
|
mortality |
18 |
|
mutation - genetics |
18 |
|
neutralizing antibodies |
18 |
|
pathogenicity |
18 |
|
pcr |
18 |
|
pneumonia |
18 |
|
population surveillance |
18 |
|
poultry - virology |
18 |
|
predictive value of tests |
18 |
|
pregnancy |
18 |
|
public health |
18 |
|
receptor binding domain |
18 |
|
seroepidemiologic studies |
18 |
|
t-lymphocytes, cytotoxic - immunology |
18 |
|
transfection |
18 |
|
age |
17 |
|
animal model |
17 |
|
antibodies, monoclonal - immunology |
17 |
|
antibody titer |
17 |
|
coronavirus - classification - genetics - isolation & purification |
17 |
|
coronavirus disease 2019 |
17 |
|
diagnosis, differential |
17 |
|
epidemics |
17 |
|
h1n1 |
17 |
|
identification |
17 |
|
influenza, human - diagnosis - virology |
17 |
|
kinetics |
17 |
|
live attenuated vaccine |
17 |
|
rat |
17 |
|
rats |
17 |
|
recombination, genetic |
17 |
|
respiratory tract infections |
17 |
|
rhinovirus |
17 |
|
rna, small interfering - genetics |
17 |
|
severe acute respiratory syndrome - drug therapy |
17 |
|
virus attachment |
17 |
|
acute disease |
16 |
|
angiogenesis |
16 |
|
avian |
16 |
|
bacterial proteins - genetics |
16 |
|
convalescence |
16 |
|
coronavirus - genetics - isolation & purification |
16 |
|
disease progression |
16 |
|
drug resistance, bacterial |
16 |
|
electrophoresis, gel, pulsed-field |
16 |
|
escherichia coli |
16 |
|
fatty acid |
16 |
|
genomics |
16 |
|
hepatitis b virus |
16 |
|
hiv |
16 |
|
hiv-1 |
16 |
|
human immunodeficiency virus |
16 |
|
immune activation |
16 |
|
immunohistochemistry |
16 |
|
inactivated vaccine |
16 |
|
influenza a virus, h1n1 subtype - genetics - immunology |
16 |
|
influenza a virus, h5n1 subtype - genetics - immunology |
16 |
|
influenza in birds - epidemiology - virology |
16 |
|
metagenomics |
16 |
|
microbiology |
16 |
|
oseltamivir |
16 |
|
penicillium marneffei |
16 |
|
protein binding |
16 |
|
reverse transcriptase polymerase chain reaction - methods |
16 |
|
rnai |
16 |
|
swine diseases - virology |
16 |
|
uplc-esi-q-tof-ms |
16 |
|
vaccination - methods |
16 |
|
virus |
16 |
|
virus evolution |
16 |
|
adaptation |
15 |
|
adenovirus |
15 |
|
alanine transaminase - blood |
15 |
|
amino acid motifs |
15 |
|
animal tissue |
15 |
|
anosmia |
15 |
|
aspergillus |
15 |
|
bacteremia |
15 |
|
betacoronavirus |
15 |
|
binding sites |
15 |
|
coronavirus - immunology |
15 |
|
cross reactions |
15 |
|
dendritic cells |
15 |
|
disease outbreaks - prevention & control |
15 |
|
dna, bacterial - chemistry - genetics |
15 |
|
drug resistance |
15 |
|
drug therapy, combination |
15 |
|
glycosylation |
15 |
|
graft rejection |
15 |
|
homozygote |
15 |
|
immunity, innate |
15 |
|
influenza a |
15 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
15 |
|
influenza a virus, h1n1 subtype - immunology - pathogenicity |
15 |
|
influenza a virus, h5n1 subtype - classification - genetics - isolation & purification |
15 |
|
influenza a virus, h5n1 subtype - immunology |
15 |
|
mask |
15 |
|
mycobacterium tuberculosis |
15 |
|
nucleoprotein |
15 |
|
olfactory dysfunction |
15 |
|
pb2 |
15 |
|
plasmids |
15 |
|
poultry |
15 |
|
remdesivir |
15 |
|
replication |
15 |
|
sars virus - genetics - isolation & purification |
15 |
|
sars virus - isolation & purification |
15 |
|
virus shedding |
15 |
|
2009 h1n1 influenza |
14 |
|
animal cell |
14 |
|
anti-bacterial agents - therapeutic use |
14 |
|
antibodies, neutralizing - blood |
14 |
|
antimicrobial |
14 |
|
asymptomatic |
14 |
|
biodiversity |
14 |
|
blood donors |
14 |
|
cell division |
14 |
|
coinfection |
14 |
|
coronavirus infection |
14 |
|
cross-reactive |
14 |
|
diagnostics |
14 |
|
disease models, animal |
14 |
|
elderly |
14 |
|
fishes - microbiology |
14 |
|
immunosuppressive agents - therapeutic use |
14 |
|
influenza a virus, h1n1 subtype - isolation and purification |
14 |
|
influenza a virus, h5n1 subtype |
14 |
|
influenza, human - immunology - pathology - virology |
14 |
|
injections, intramuscular |
14 |
|
intestine |
14 |
|
lymphocyte activation |
14 |
|
macrophages |
14 |
|
membrane glycoproteins - metabolism |
14 |
|
models, biological |
14 |
|
nf-kappa b - metabolism |
14 |
|
plasma |
14 |
|
protease |
14 |
|
protein conformation |
14 |
|
real-time pcr |
14 |
|
rhizopus microsporus |
14 |
|
rna interference |
14 |
|
sars virus - metabolism - pathogenicity |
14 |
|
sars-cov-2 variants |
14 |
|
spike |
14 |
|
spike glycoprotein |
14 |
|
staphylococcus aureus |
14 |
|
tumor cells, cultured |
14 |
|
virus replication - physiology |
14 |
|
amino acid substitution - genetics |
13 |
|
anti-bacterial agents |
13 |
|
antibiotic prophylaxis |
13 |
|
antibodies |
13 |
|
antiviral agents - pharmacology |
13 |
|
bird diseases - epidemiology - virology |
13 |
|
bismuth |
13 |
|
bunyavirales |
13 |
|
carcinoma, hepatocellular - genetics - metabolism |
13 |
|
carrier state - microbiology |
13 |
|
cats |
13 |
|
cell differentiation |
13 |
|
chicken |
13 |
|
clarithromycin |
13 |
|
conjunctivitis |
13 |
|
corticosteroid |
13 |
|
covid‐19 |
13 |
|
cytokine and chemokine response |
13 |
|
cytokines - metabolism |
13 |
|
d222g |
13 |
|
diarrhea - microbiology |
13 |
|
disease reservoirs |
13 |
|
dna vaccine |
13 |
|
dna, bacterial - genetics |
13 |
|
food microbiology |
13 |
|
immunization |
13 |
|
immunoglobulin g - blood |
13 |
|
infection control |
13 |
|
influenza, human - immunology |
13 |
|
influenza, human - mortality |
13 |
|
intradermal |
13 |
|
laribacter hongkongensis |
13 |
|
liver neoplasms - genetics - metabolism |
13 |
|
mers |
13 |
|
mice, nude |
13 |
|
nsp16 |
13 |
|
nucleocapsid proteins - genetics - immunology |
13 |
|
point mutation |
13 |
|
polymorphism, single nucleotide |
13 |
|
receptors, cell surface - metabolism |
13 |
|
ribavirin |
13 |
|
s. aureus |
13 |
|
sace2 |
13 |
|
sars virus - drug effects |
13 |
|
sequence homology, nucleic acid |
13 |
|
severe acute respiratory syndrome - diagnosis - virology |
13 |
|
species index: fungi |
13 |
|
staphylococcal infections - microbiology |
13 |
|
streptococcus pneumoniae |
13 |
|
t-lymphocytes - immunology |
13 |
|
acute hepatitis |
12 |
|
airborne |
12 |
|
antibiotic resistance |
12 |
|
astroviridae - classification - genetics - isolation and purification |
12 |
|
astroviridae infections - epidemiology - veterinary - virology |
12 |
|
bacteremia - microbiology |
12 |
|
bacteriological techniques |
12 |
|
balb/c mice |
12 |
|
case report |
12 |
|
chronic obstructive lung disease |
12 |
|
combination therapy |
12 |
|
controlled study |
12 |
|
copd |
12 |
|
dna primers - genetics |
12 |
|
enterobacteriaceae |
12 |
|
false positive |
12 |
|
feces - microbiology |
12 |
|
genetic vectors |
12 |
|
hepatitis e |
12 |
|
immunotherapy |
12 |
|
infant, newborn |
12 |
|
infectivity |
12 |
|
influenza a virus, h5n1 subtype - classification - genetics |
12 |
|
influenza a virus, h5n1 subtype - immunology - pathogenicity |
12 |
|
influenza, human - epidemiology - immunology - virology |
12 |
|
influenza, human - epidemiology - pathology - virology |
12 |
|
influenza, human - epidemiology - transmission - virology |
12 |
|
kawasaki disease |
12 |
|
lopinavir |
12 |
|
macrophage |
12 |
|
methicillin resistance |
12 |
|
methicillin-resistant staphylococcus aureus |
12 |
|
molecular diagnostic techniques - methods |
12 |
|
nose - virology |
12 |
|
novel species |
12 |
|
omicron variant |
12 |
|
open reading frames |
12 |
|
organ size |
12 |
|
polymorphism, restriction fragment length |
12 |
|
proteomics |
12 |
|
pseudomonas aeruginosa |
12 |
|
randomized controlled trial |
12 |
|
rna, messenger - genetics - metabolism |
12 |
|
rna, ribosomal, 16s - genetics |
12 |
|
rna, viral - metabolism |
12 |
|
rt-lamp |
12 |
|
sars-cov-2 rbd igg |
12 |
|
sftsv |
12 |
|
t cell response |
12 |
|
tomography, x-ray computed |
12 |
|
urine - virology |
12 |
|
viral persistence |
12 |
|
viral shedding |
12 |
|
virus cultivation |
12 |
|
2′-o-methyltransferase |
11 |
|
acute respiratory illness |
11 |
|
algorithms |
11 |
|
animal models |
11 |
|
animals, wild - virology |
11 |
|
anthranilic acid |
11 |
|
antibodies, viral - biosynthesis |
11 |
|
antifungal agents - therapeutic use |
11 |
|
antiviral agents - chemical synthesis - chemistry - pharmacology |
11 |
|
asian continental ancestry group |
11 |
|
ba.5.2 |
11 |
|
bacteriological techniques - methods |
11 |
|
bone marrow transplantation - immunology |
11 |
|
broad spectrum |
11 |
|
carboxypeptidases - antagonists & inhibitors - metabolism |
11 |
|
cell adhesion molecules - genetics - metabolism |
11 |
|
cell proliferation |
11 |
|
cell transformation, neoplastic |
11 |
|
chemokine |
11 |
|
cho cells - virology |
11 |
|
contamination |
11 |
|
cricetulus |
11 |
|
diagnostic |
11 |
|
diarrhea - epidemiology - microbiology |
11 |
|
dna, bacterial - analysis |
11 |
|
dna, viral - blood |
11 |
|
dose-response relationship, drug |
11 |
|
down-regulation |
11 |
|
dromedary camels |
11 |
|
drug resistance, bacterial - genetics |
11 |
|
drug synergism |
11 |
|
drug therapy, combination - therapeutic use |
11 |
|
ducks - virology |
11 |
|
early diagnosis |
11 |
|
endoplasmic reticulum |
11 |
|
entry |
11 |
|
enzyme-linked immunosorbent assay - methods |
11 |
|
feces analysis |
11 |
|
fluorescent antibody technique, indirect |
11 |
|
fungi |
11 |
|
gene deletion |
11 |
|
genes, bacterial |
11 |
|
genes, rrna |
11 |
|
glycoprotein |
11 |
|
graft survival |
11 |
|
hand |
11 |
|
hcov-229e |
11 |
|
infectiousness |
11 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
11 |
|
influenza a virus, h5n1 subtype - pathogenicity |
11 |
|
influenza in birds - epidemiology - transmission - virology |
11 |
|
influenza vaccines - immunology |
11 |
|
influenza, human - epidemiology |
11 |
|
influenza, human - immunology - virology |
11 |
|
intestine, small - physiology |
11 |
|
isolation |
11 |
|
kidney transplantation |
11 |
|
lectins, c-type - genetics - metabolism |
11 |
|
lung - physiology - virology |
11 |
|
membrane glycoproteins - genetics |
11 |
|
murine |
11 |
|
n501y |
11 |
|
neutralization |
11 |
|
next-generation sequencing |
11 |
|
nucleic acid conformation |
11 |
|
open reading frames - genetics |
11 |
|
phage display |
11 |
|
pharynx - virology |
11 |
|
plasmids - genetics |
11 |
|
proteasome endopeptidase complex - metabolism |
11 |
|
receptors, cell surface - genetics - metabolism |
11 |
|
respiratory tract infection |
11 |
|
rna, messenger - analysis |
11 |
|
sars virus - drug effects - growth & development - metabolism - physiology |
11 |
|
sars virus - genetics |
11 |
|
severe acute respiratory syndrome - epidemiology - genetics |
11 |
|
severe acute respiratory syndrome - epidemiology - immunology - virology |
11 |
|
species index: animalia |
11 |
|
statistics, nonparametric |
11 |
|
sterilizing immunity |
11 |
|
stool |
11 |
|
structure-activity relationship |
11 |
|
t-cell response |
11 |
|
talaromyces marneffei |
11 |
|
tandem repeat sequences |
11 |
|
tsukamurella |
11 |
|
vero cells - virology |
11 |
|
viral envelope proteins - genetics - immunology |
11 |
|
viral matrix proteins - antagonists & inhibitors - metabolism |
11 |
|
virology |
11 |
|
zoonosis |
11 |
|
adaptor proteins, signal transducing - genetics - immunology - metabolism |
10 |
|
adiponectin |
10 |
|
adoptive transfer |
10 |
|
age distribution |
10 |
|
aids |
10 |
|
airborne infection |
10 |
|
alleles |
10 |
|
animals, domestic - virology |
10 |
|
antibody specificity |
10 |
|
antigen-presentation |
10 |
|
asia |
10 |
|
autoantibodies - blood |
10 |
|
autoantibody |
10 |
|
autophagy |
10 |
|
bacteria |
10 |
|
bats |
10 |
|
bayes theorem |
10 |
|
bird diseases - virology |
10 |
|
blood culture |
10 |
|
body weight |
10 |
|
canada - epidemiology |
10 |
|
cancer |
10 |
|
cell separation |
10 |
|
cell tropism |
10 |
|
chick embryo |
10 |
|
circular dichroism |
10 |
|
combined modality therapy |
10 |
|
community-acquired infections - epidemiology - microbiology |
10 |
|
conserved sequence |
10 |
|
convalescent |
10 |
|
coronavirus - classification - genetics |
10 |
|
coronavirus - immunology - pathogenicity - physiology |
10 |
|
coronavirus infections - immunology - virology |
10 |
|
covid19 |
10 |
|
culture media |
10 |
|
cyclooxygenase 2 - biosynthesis - genetics |
10 |
|
cyclooxygenase 2 inhibitors |
10 |
|
cytokines - biosynthesis - immunology |
10 |
|
cytokines - blood |
10 |
|
cytomegalovirus |
10 |
|
cytopathogenic effect, viral |
10 |
|
d225g |
10 |
|
damplicon |
10 |
|
dead-box rna helicases - genetics - immunology - metabolism |
10 |
|
disease outbreaks - history |
10 |
|
disease severity |
10 |
|
drug interactions |
10 |
|
ecosystem |
10 |
|
epithelial cells - immunology - metabolism |
10 |
|
erythromycin - pharmacology |
10 |
|
etiology |
10 |
|
gene |
10 |
|
genetics |
10 |
|
genome, bacterial |
10 |
|
hemagglutinin glycoproteins, influenza virus - genetics |
10 |
|
hemagglutinin glycoproteins, influenza virus - genetics - metabolism |
10 |
|
hepatitis |
10 |
|
history, 20th century |
10 |
|
history, 21st century |
10 |
|
hospitalization - statistics and numerical data |
10 |
|
human adenovirus |
10 |
|
human neutralizing antibody |
10 |
|
immunoassay - methods |
10 |
|
immunogenicity |
10 |
|
immunology |
10 |
|
infectious disease |
10 |
|
influenza a virus - isolation & purification |
10 |
|
influenza a virus, h1n1 subtype - physiology |
10 |
|
influenza a virus, h5n1 subtype - genetics - immunology - pathogenicity |
10 |
|
influenza a virus, h5n1 subtype - metabolism |
10 |
|
influenza a virus, h5n1 subtype - physiology |
10 |
|
influenza h1n1 |
10 |
|
influenza in birds - enzymology - immunology - virology |
10 |
|
influenza, human - enzymology - virology |
10 |
|
influenza, human - immunology - metabolism - virology |
10 |
|
influenza, human - metabolism - transmission |
10 |
|
interferon regulatory factor-3 - metabolism |
10 |
|
janus kinases - immunology |
10 |
|
kidney transplantation - adverse effects |
10 |
|
linker-immunodominant site |
10 |
|
lipid peroxidation |
10 |
|
liver function tests |
10 |
|
logistic models |
10 |
|
lung injury |
10 |
|
macaca mulatta |
10 |
|
macrophages - immunology |
10 |
|
macrophages - immunology - metabolism |
10 |
|
masks |
10 |
|
membrane glycoproteins - immunology |
10 |
|
mice, inbred c57bl |
10 |
|
middle east |
10 |
|
models, theoretical |
10 |
|
molecular structure |
10 |
|
mouth - microbiology |
10 |
|
mrna |
10 |
|
ms |
10 |
|
multivariate analysis |
10 |
|
mycobacterium |
10 |
|
nasal turbinate |
10 |
|
neoplasm transplantation |
10 |
|
neuraminidase - genetics |
10 |
|
npc |
10 |
|
orthomyxoviridae infections - epidemiology - transmission - veterinary - virology |
10 |
|
p38 mitogen-activated protein kinases - metabolism |
10 |
|
paracrine communication - immunology |
10 |
|
patient admission - statistics and numerical data |
10 |
|
penicillium - genetics |
10 |
|
peptide |
10 |
|
picornaviridae - chemistry - classification - genetics - isolation and purification |
10 |
|
pneumonia, viral - immunology - virology |
10 |
|
pulmonary alveoli - immunology - metabolism |
10 |
|
rats, sprague-dawley |
10 |
|
receptor, interferon alpha-beta - immunology |
10 |
|
recombination |
10 |
|
recurrence |
10 |
|
reverse genetics |
10 |
|
rna, viral - genetics - isolation & purification |
10 |
|
rt-pcr |
10 |
|
sars virus - genetics - immunology |
10 |
|
sars virus - isolation and purification |
10 |
|
sars virus - physiology |
10 |
|
seasonality |
10 |
|
sequence deletion |
10 |
|
sequence homology |
10 |
|
sequencing |
10 |
|
seroprevalence |
10 |
|
severe acute respiratory syndrome - diagnosis |
10 |
|
severe acute respiratory syndrome - epidemiology - transmission - virology |
10 |
|
severe acute respiratory syndrome - prevention & control |
10 |
|
severe acute respiratory syndrome - virology |
10 |
|
sialic acid |
10 |
|
smell impairment |
10 |
|
specific |
10 |
|
steroid |
10 |
|
swine-origin |
10 |
|
symptoms |
10 |
|
toll-like receptor 3 - metabolism |
10 |
|
transplantation, heterologous |
10 |
|
upper respiratory tract |
10 |
|
vaccines, dna - administration & dosage - immunology |
10 |
|
vietnam - epidemiology |
10 |
|
viral proteins - chemistry - genetics |
10 |
|
zika virus |
10 |
|
zoonoses |
10 |
|
3c-like protease |
9 |
|
5' untranslated regions |
9 |
|
a(h1n1)pdm09 |
9 |
|
a(h3n2) |
9 |
|
adenosine synthase a |
9 |
|
adjuvant |
9 |
|
aged mice |
9 |
|
airway organoid |
9 |
|
antibiotic sensitivity |
9 |
|
antibodies, viral - blood - immunology |
9 |
|
antibody detection |
9 |
|
antibody formation |
9 |
|
antibody-dependent cell-mediated cytotoxicity |
9 |
|
antigenic variation |
9 |
|
antigens, cd - metabolism |
9 |
|
antitubercular agents - therapeutic use |
9 |
|
antiviral agents - administration and dosage - therapeutic use |
9 |
|
asia, southeastern |
9 |
|
asymptomatic infection |
9 |
|
autoantibodies |
9 |
|
avian influenza virus |
9 |
|
bacteraemia |
9 |
|
bacteremia - epidemiology - microbiology |
9 |
|
bagg albino mouse |
9 |
|
bioaerosols |
9 |
|
biological markers - blood |
9 |
|
bocavirus - classification - genetics - isolation and purification |
9 |
|
celecoxib |
9 |
|
cell culture |
9 |
|
cell surface |
9 |
|
chiroptera - classification - virology |
9 |
|
chromatin accessibility |
9 |
|
circrna |
9 |
|
clinical outcome |
9 |
|
community-acquired infections - microbiology |
9 |
|
comorbidity |
9 |
|
consensus sequence |
9 |
|
coronavac |
9 |
|
coronavirus infections - genetics |
9 |
|
coronavirus infections - veterinary - virology |
9 |
|
cross infection - epidemiology - immunology |
9 |
|
cross-protection |
9 |
|
cytokines - biosynthesis |
9 |
|
deleted in liver cancer 2 |
9 |
|
diagnostic errors |
9 |
|
diversity |
9 |
|
dna fingerprinting |
9 |
|
dna, viral - chemistry - genetics |
9 |
|
dogs - virology |
9 |
|
dromedary camel |
9 |
|
drug resistance, viral |
9 |
|
drug resistance, viral - genetics |
9 |
|
emerging |
9 |
|
epidemic |
9 |
|
epithelial cells - virology |
9 |
|
epstein–barr virus |
9 |
|
ex vivo |
9 |
|
ex vivo human lung tissues |
9 |
|
fc-rbd |
9 |
|
fluorescent antibody technique |
9 |
|
gene therapy |
9 |
|
genome mutation |
9 |
|
glycoproteins - metabolism |
9 |
|
gram-negative bacterial infections - diagnosis - microbiology |
9 |
|
h1n1 influenza virus |
9 |
|
hku1 |
9 |
|
hospitals, university |
9 |
|
host-virus interaction |
9 |
|
hot temperature |
9 |
|
human coronavirus hku1 |
9 |
|
human primary nasal epithelial cells |
9 |
|
human respiratory syncytial virus |
9 |
|
illumina sequencing |
9 |
|
immune imprinting |
9 |
|
immune protection |
9 |
|
immunization, secondary |
9 |
|
immunoglobulin g - analysis - immunology |
9 |
|
immunotherapy - methods |
9 |
|
influenza a virus - pathogenicity |
9 |
|
influenza a virus - physiology |
9 |
|
influenza a virus, h1n1 subtype - classification - genetics - isolation and purification - physiology |
9 |
|
influenza a virus, h1n1 subtype - genetics - isolation and purification - physiology |
9 |
|
influenza b |
9 |
|
influenza vaccines - administration and dosage |
9 |
|
influenza, human - epidemiology - prevention & control - transmission - virology |
9 |
|
influenza-virus |
9 |
|
injections, intravenous |
9 |
|
internalization |
9 |
|
kidney - cytology |
9 |
|
lethal mouse model |
9 |
|
liver diseases - epidemiology |
9 |
|
liver transplantation - statistics & numerical data |
9 |
|
lung damage |
9 |
|
lung pathology |
9 |
|
lupus erythematosus, systemic - complications |
9 |
|
mamastrovirus - classification - genetics - isolation & purification |
9 |
|
mass spectrometry |
9 |
|
membrane glycoproteins - analysis |
9 |
|
membrane glycoproteins - chemistry - genetics |
9 |
|
mesalazine |
9 |
|
mice, scid |
9 |
|
microcephaly |
9 |
|
middle east respiratory syndrome |
9 |
|
middle east respiratory syndrome coronavirus |
9 |
|
mitochondria |
9 |
|
model |
9 |
|
models, chemical |
9 |
|
models, genetic |
9 |
|
molecular diagnosis |
9 |
|
molnupiravir |
9 |
|
myocardial infarction - mortality - prevention and control |
9 |
|
nanopore sequencing |
9 |
|
nmr |
9 |
|
nucleocapsid proteins - genetics |
9 |
|
nucleolin |
9 |
|
operating rooms |
9 |
|
orchitis |
9 |
|
orf3a |
9 |
|
orthomyxoviridae infections - immunology - mortality - physiopathology - virology |
9 |
|
parvoviridae infections - veterinary - virology |
9 |
|
peptides - metabolism |
9 |
|
peritonitis |
9 |
|
phosphatidic acid phosphatases |
9 |
|
phylogenetic tree |
9 |
|
plasmid |
9 |
|
pneumococcal vaccines - administration and dosage |
9 |
|
pneumonia, viral - epidemiology - immunology - virology |
9 |
|
pneumonia, viral - virology |
9 |
|
point-of-care testing |
9 |
|
post-ba.2/5 subvariants |
9 |
|
promoter regions, genetic - genetics |
9 |
|
proximal differentiation |
9 |
|
reagent kits, diagnostic |
9 |
|
recombinant proteins - analysis - immunology |
9 |
|
renal transplant |
9 |
|
respiratory |
9 |
|
respiratory syncytial virus |
9 |
|
respiratory virus |
9 |
|
resting-state fmri |
9 |
|
ribosomes - genetics - metabolism |
9 |
|
rig-i |
9 |
|
rna, viral - analysis |
9 |
|
rna, viral - analysis - genetics |
9 |
|
sars virus |
9 |
|
sars virus - metabolism |
9 |
|
sars-cov-2 variants of concern |
9 |
|
sars‐cov‐2 |
9 |
|
screening |
9 |
|
seroepidemiology |
9 |
|
severe acute respiratory syndrome - immunology - virology |
9 |
|
smoking |
9 |
|
stroke - mortality - prevention and control |
9 |
|
swine - blood - virology |
9 |
|
swine diseases - blood - epidemiology - transmission - virology |
9 |
|
taxonomy |
9 |
|
testis |
9 |
|
th1 cells - immunology |
9 |
|
tissue donors |
9 |
|
transplantation, homologous |
9 |
|
transplantation, homologous - adverse effects |
9 |
|
tumor microenvironment |
9 |
|
vaccines, inactivated - administration & dosage - immunology |
9 |
|
vancomycin resistance |
9 |
|
vero cells |
9 |
|
victoria lineage |
9 |
|
viral envelope proteins - analysis |
9 |
|
viral envelope proteins - chemistry - genetics |
9 |
|
viral envelope proteins - metabolism |
9 |
|
viral matrix proteins - genetics |
9 |
|
viral proteins - genetics - metabolism |
9 |
|
virulence factors |
9 |
|
vitamin a |
9 |
|
vopba |
9 |
|
weanling mice |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
xbb.1 |
9 |
|
zanamivir |
9 |
|
25-hydroxycholesterol |
8 |
|
3clpro inhibitor |
8 |
|
acute infection |
8 |
|
adeno-associated virus |
8 |
|
aerosolised |
8 |
|
allosteric-site inhibitor |
8 |
|
am580 |
8 |
|
antibiotic susceptibility |
8 |
|
antibodies, monoclonal - diagnostic use |
8 |
|
antibodies, viral - genetics - immunology - metabolism |
8 |
|
antibodies, viral - immunology |
8 |
|
antibody blood level |
8 |
|
antibody response |
8 |
|
antigens, cd - genetics - metabolism |
8 |
|
antiviral agents |
8 |
|
antiviral agents - chemical synthesis - pharmacology |
8 |
|
asia - epidemiology |
8 |
|
aspergillus fumigatus |
8 |
|
autopsy |
8 |
|
avian influenza a virus |
8 |
|
b cell |
8 |
|
b-cell suppression |
8 |
|
bacterium |
8 |
|
biliary atresia - complications - surgery |
8 |
|
binding sites - genetics |
8 |
|
bioaerosol |
8 |
|
biology |
8 |
|
biopsy |
8 |
|
biotechnology technology: comprehensive works medical sciences chemistry |
8 |
|
blotting, southern |
8 |
|
broad-spectrum antiviral treatment |
8 |
|
bronchi - immunology - pathology |
8 |
|
carrier proteins - metabolism |
8 |
|
case study |
8 |
|
caspase |
8 |
|
chemical genetics |
8 |
|
chemokines |
8 |
|
chi-square distribution |
8 |
|
child day care centers |
8 |
|
chromatography, high pressure liquid |
8 |
|
chronic infection |
8 |
|
cilia |
8 |
|
clade 2.3.4.4b |
8 |
|
clostridium difficile |
8 |
|
community-acquired infections |
8 |
|
complications of liver transplantation |
8 |
|
computational biology - methods |
8 |
|
conjunctiva |
8 |
|
coronavirus hku1 |
8 |
|
coronavirus infections - epidemiology - physiopathology - virology |
8 |
|
coronaviruses |
8 |
|
covid-19 vaccine |
8 |
|
cross-species transmission |
8 |
|
crystal structure |
8 |
|
cyclosporine - therapeutic use |
8 |
|
cytokines - genetics - metabolism |
8 |
|
cytokines - immunology |
8 |
|
cytotoxicity, immunologic |
8 |
|
databases, nucleic acid - statistics & numerical data |
8 |
|
debridement |
8 |
|
delns1-ncov-rbd laiv |
8 |
|
dendritic cell |
8 |
|
dendritic cells - immunology |
8 |
|
detection |
8 |
|
diagnostic test evaluation |
8 |
|
dialysis |
8 |
|
dipeptidyl peptidase 4 |
8 |
|
dog diseases - virology |
8 |
|
early |
8 |
|
elisa |
8 |
|
emc |
8 |
|
epstein-barr virus (ebv) |
8 |
|
extended-spectrum beta-lactamases |
8 |
|
family characteristics |
8 |
|
feasibility studies |
8 |
|
functional brain network |
8 |
|
ganglioside gm1 antibody |
8 |
|
gastroenteritis |
8 |
|
gastroenteritis - microbiology |
8 |
|
gastrointestinal diseases - microbiology |
8 |
|
gene amplification |
8 |
|
gene expression regulation, bacterial |
8 |
|
gene expression regulation, viral |
8 |
|
genes, bacterial - genetics |
8 |
|
genes, viral - genetics |
8 |
|
genetic vectors - genetics |
8 |
|
genome, fungal |
8 |
|
glycolipids |
8 |
|
glycoproteins - genetics - metabolism |
8 |
|
gram-positive bacterial infections - microbiology |
8 |
|
hcov-emc |
8 |
|
hepatitis b vaccination |
8 |
|
high throughput screening |
8 |
|
high-risk |
8 |
|
hiv infections - genetics - metabolism |
8 |
|
hospitalized |
8 |
|
hpai |
8 |
|
human exhaled breath |
8 |
|
human rhinovirus |
8 |
|
hypsugo bat |
8 |
|
il-8 |
8 |
|
imiquimod |
8 |
|
immunization schedule |
8 |
|
immunocompetence |
8 |
|
immunosuppression |
8 |
|
immunosuppressive agents - adverse effects - therapeutic use |
8 |
|
incidence rates |
8 |
|
influenza a virus - classification - genetics - pathogenicity |
8 |
|
influenza a virus, h1n1 subtype - genetics - isolation & purification - physiology |
8 |
|
influenza a virus, h1n1 subtype - isolation & purification - pathogenicity |
8 |
|
influenza a virus, h1n1 subtype - pathogenicity |
8 |
|
influenza a virus, h5n1 subtype - genetics - physiology |
8 |
|
influenza a virus, h5n1 subtype - isolation & purification - pathogenicity |
8 |
|
influenza b virus |
8 |
|
influenza vaccines |
8 |
|
integrative-omics |
8 |
|
interferon beta-1b |
8 |
|
interferon lambda 1 |
8 |
|
interventions |
8 |
|
intranasal |
8 |
|
intraoperative complications - epidemiology |
8 |
|
invasive pneumococcal disease |
8 |
|
ip-10 |
8 |
|
leukocytes - virology |
8 |
|
lipid |
8 |
|
liver diseases - etiology - surgery |
8 |
|
liver transplantation - adverse effects - statistics & numerical data |
8 |
|
liver transplantation - contraindications - methods - mortality - statistics & numerical data |
8 |
|
liver transplantation - methods |
8 |
|
living donor liver transplant |
8 |
|
living-related liver transplantation |
8 |
|
long covid |
8 |
|
mammary gland |
8 |
|
marmosets |
8 |